Fabrication of multifunctional microfibrous and nanofibrous cellulose carriers and comparison of cell adhesion and spreading potential on them

Fibrous biomaterials have received much attention in tissue engineering and regenerative medicine due to their morphology, resembling extracellular matrix. In comparison to synthetic fibers, cellulose based fibers have interesting properties for cellular applications such as biodegradability, biocompatibility, simple preparation and their potential for chemical modification. Among cellulose derivatives, carboxymethyl cellulose and quaternized cellulose are the most important and valuable cellulose ethers which have anionic and cationic surface charge. In this research, we report the fabrication of multifunctional cellulose microfibrous and nanofibrous scaffolds and the comparison of adhesion and spreading potential of human fibroblast cell on them. The fabricated fibrous scaffolds were characterized by several instrumental techniques. The results showed that multifunctional cellulose nanofibers and microfiber had 8.6 and 8.2 mV surface potential, 7.1 and 6.8 MPa tensile strength, 560 and 510 MPa Young modules, 610 and 595 water uptake and 41o and 44o contact angle, respectively. The MTT assay showed that proliferation of fibroblast cells was enhanced in nanofibrous, compared to microfibrous mat. The SEM analysis of fixed cells on scaffolds showed that cells spreading on nanofibrous samples became more noticeable than microfibrous ones. © 2020 by the authors

Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms

Approximately 20% of patients with myeloproliferative neoplasms (MPN) harbor mutations in the gene calreticulin (CALR), with 80% of those mutations classified as either type I or type II. While type II CALR-mutant proteins retain many of the Ca2+ binding sites present in the wild-type protein, type I CALR-mutant proteins lose these residues. The functional consequences of this differential loss of Ca2+ binding sites remain unexplored. Here, we show that the loss of Ca2+ binding residues in the type I mutant CALR protein directly impairs its Ca2+ binding ability, which in turn leads to depleted endoplasmic reticulum (ER) Ca2+ and subsequent activation of the IRE1α/XBP1 pathway of the unfolded protein response. Genetic or pharmacologic inhibition of IRE1α/XBP1 signaling induces cell death in type I mutant but not type II mutant or wild-type CALR-expressing cells, and abrogates type I mutant CALR-driven MPN disease progression in vivo. Significance: Current targeted therapies for CALR-mutated MPNs are not curative and fail to differentiate between type I- versus type II-driven disease. To improve treatment strategies, it is critical to identify CALR mutation type-specific vulnerabilities. Here we show that IRE1α/XBP1 represents a unique, targetable dependency specific to type I CALR-mutated MPNs